IMPERIA GRAND Wrote:
У нас поздно смотреть. В подопытные кролики уже попал. Отказаться практически невозможно.
Потом если что, отпишусь.
вот итальянцы есть, но тут речь скорее всего идет о перспективах бустирования третьей дозой Спутника, после пфайзера, потому что у него эффективность снижается намного сильнее
в любом случае, совместное использование допускается и даже рекомендуется
https://www.medrxiv.org/content/10.1101/2022.01.15.22269335v1.full-textQuote:
The new variant Omicron (B.1.1.529) of SARS-CoV-2, first identified in November 2021, is rapidly spreading all around the world. The Omicron becomes the dominant variant of SARS-CoV-2. There are many ongoing studies evaluating the effectiveness of existing vaccines. Studies on neutralizing activity of vaccinated sera against Omicron variant are currently being carried out in many laboratories.
In this study, we have shown the neutralizing activity of sera against SARS-CoV-2 Omicron (B.1.1.529) variant compared to the reference Wuhan D614G (B.1) variant in individuals vaccinated with 2 doses of Sputnik V or BNT162b2 in different time points up to 6 months after vaccination. We performed analysis on sample pools with comparable NtAb to Wuhan D614G variant. The decrease in neutralizing antibody (NtAb) to the Omicron variant was 8.1 folds for group of Sputnik V-vaccinated and 21.4 folds for group of BNT162b2-vaccinated. Analysis showed that 74.2% of Sputnik V- and 56.9% of BNT162b2-vaccinated sera had detectable NtAb to SARS-CoV-2 Omicron variant.
The decrease in NtAb to SARS-CoV-2 Omicron variant compared to Wuhan variant has been shown for many COVID-19 vaccines in use, with some showing no neutralization at all. Today the necessity of third booster vaccination is obvious. And the most effective approach, already shown in several studies, is the use of heterologous booster vaccination pioneered in COVID-19 vaccines by Sputnik V.
ntroduction
As of Jan 12, 2022, the Omicron variant has been confirmed in at least 150 countries around the world [1]. From Jan 03, 2022 to Jan 09, 2022 Omicron variant accounts for roughly 62.5 percent of all SARS-CoV-2 sequences available on GISAID database [2].
Today, the effectiveness of existing vaccines against the new Omicron variant is the question of high priority. Around the world, studies are being carried out to analyze the neutralization activity of the sera of vaccinated people against the Omicron variant.
It was shown, that sera from vaccinated individuals with 2 doses BNT162b2 or mRNA-1273 has 22-30-fold decrease in neutralizing activity against the Omicron variant compared with wild type virus [3-4]. A similar decrease in neutralizing activity was shown in other study comparing two vaccines: ChAdOx1-nCoV-19 and BNT162b2 [4-5]. A study was conducted in China comparing the effectiveness of the BNT162b2 and Coronavac vaccines. According to the results of the study, the complete no neutralizing antibodies against the Omicron variant was shown in individuals vaccinated with Coronavac [6].
However, many studies have shown that administration of 3 doses of vaccine or a combination of disease and vaccination significantly increases the titer of virus-neutralizing antibodies to Omicron variant [7-8]. Analysis of sera of individuals only vaccinated with BNT162b2, mRNA-1273 or Ad26.COV2.S shown the decrease in neutralizing activity against the Omicron variant from 23 to 122 folds. In case of combination of infection and vaccination, the decrease in titers was from 4 to 13 folds [9].
In this study, we have shown the neutralizing activity of sera against Omicron variant in individuals vaccinated with 2 doses of Sputnik V or BNT162b2 in different time points after vaccination and in Sputnik V-vaccinated individuals with a history of COVID-19.
